Cardiovascular Medications and Oral Health Implications

Core Review

Overview of Cardiovascular Drug Classes

Beta Blockers

Mechanism: Competitive antagonists at beta-adrenergic receptors.

• Cardioselective (β1-selective): Metoprolol, atenolol, bisoprolol, esmolol. Block β1 receptors in the heart → decreased HR, contractility, conduction velocity, and renin release. At therapeutic doses, minimal β2 blockade.
• Non-selective (β1 + β2): Propranolol, nadolol, timolol. Block both β1 and β2 receptors.

Oral adverse effects:

• Xerostomia and dysgeusia (altered taste) — more common with propranolol (non-selective)
• Lichenoid drug reactions (white reticular or erosive lesions resembling oral lichen planus) — associated with beta blockers, ACE inhibitors, NSAIDs, and many other drugs
• Exacerbation of psoriasis (beta blockers can worsen psoriasis)

Epinephrine interaction with beta blockers — a debated clinical topic: The concern: Non-selective beta blockers block β2 vasodilation in skeletal muscle → "unopposed α1" vasoconstriction with epinephrine administration → theoretical hypertensive crisis and reflex bradycardia.

Current consensus: This interaction is primarily a concern with HIGH doses of epinephrine (e.g., epinephrine for anaphylaxis) and with non-selective beta blockers (propranolol, nadolol). For dental LA with standard epinephrine concentrations (1:100,000), the amount of epinephrine is small, and significant adverse effects from unopposed alpha stimulation are highly unlikely in stable patients. Most authorities, including the AHA and ADA, do NOT consider beta blocker therapy a contraindication to epinephrine-containing LA for dental procedures in stable patients. Aspiration and limitation of the total epinephrine dose remain standard precautions.

Clinical approach: For a patient on a non-selective beta blocker, use epinephrine-containing LA with aspiration and limit the total epinephrine dose. For elective dental procedures in a patient with unstable cardiovascular disease, defer treatment pending medical optimization. For patients taking cardioselective beta blockers (metoprolol, atenolol), the interaction is not clinically significant at dental LA doses.

ACE Inhibitors and ARBs

ACE inhibitors (lisinopril, enalapril):

• Block conversion of angiotensin I → angiotensin II → vasodilation, decreased aldosterone, decreased BP
• Also inhibit bradykinin degradation → increased bradykinin levels

Oral/dental implications:

• Dry cough (10-20% of patients): Due to increased bradykinin and substance P. NOT true xerostomia — the cough is from bronchial irritation. Important to distinguish from xerostomia.
• Angioedema (rare, 0.1-0.7%): Bradykinin-mediated swelling of lips, tongue, face, oropharynx. Can be life-threatening if laryngeal involvement. More common in Black patients. Can occur after months to years of uneventful therapy. Dental procedures and NSAID use may be triggers in susceptible patients. If angioedema occurs, discontinue ACE inhibitor and switch to ARB (ARBs do not affect bradykinin and do not cause angioedema with the same frequency).
• Dysgeusia (altered taste, metallic taste): ACE inhibitors contain a sulfhydryl group (captopril) or may affect zinc metabolism; taste disturbance is reported.
• Burning mouth syndrome
• Lichenoid reactions

ARBs (losartan, valsartan):

• Block angiotensin II AT1 receptors directly → vasodilation, decreased aldosterone
• Do NOT increase bradykinin → NO cough, LESS angioedema (though rare cases reported)
• Similar oral effects: dysgeusia, possible xerostomia

NSAID interaction: Both ACE inhibitors and ARBs rely in part on vasodilatory prostaglandins for their antihypertensive effect. NSAIDs can reduce the antihypertensive efficacy by blocking prostaglandin synthesis, and the combination increases the risk of acute kidney injury (especially in volume-depleted, elderly, or renally impaired patients). Short-term NSAID use for dental pain is generally safe, but consider the patient's renal function and volume status.

Calcium Channel Blockers (CCBs)

Mechanism: Block L-type voltage-gated calcium channels in cardiac and vascular smooth muscle → reduced intracellular Ca2+ → vasodilation (dihydropyridines) and/or decreased cardiac contractility and conduction (non-dihydropyridines).

• Dihydropyridines (DHP): Nifedipine, amlodipine, felodipine. Primarily vasodilators.
• Non-dihydropyridines (non-DHP): Verapamil, diltiazem. Cardiac conduction effects + vasodilation.

Drug-Induced Gingival Overgrowth (DIGO) — A CRITICAL NBDHE TOPIC

The classic triad of drug-induced gingival overgrowth:

1. Nifedipine (calcium channel blocker) — the most commonly implicated CCB
2. Phenytoin (anticonvulsant, Dilantin) — approximately 50% of patients develop gingival overgrowth
3. Cyclosporine (immunosuppressant) — used in transplant patients

Key NBDHE concept: NOT ALL CCBs are equal for gingival overgrowth. Nifedipine is the MOST COMMON CCB causing gingival overgrowth. Amlodipine causes gingival overgrowth much LESS frequently. Verapamil and diltiazem are rarely implicated. The NBDHE may ask: "Which calcium channel blocker is most associated with gingival overgrowth?" → Nifedipine.

Clinical features of drug-induced gingival overgrowth:

• Begins at the INTERDENTAL PAPILLAE (between teeth)
• Enlargement of the free and attached gingiva
• Firm, fibrotic, pink (unless secondary inflammation present)
• Painless, non-hemorrhagic (unless inflamed)
• May cover clinical crowns, interfere with function, esthetics, and oral hygiene
• Onset typically within 1-3 months of starting the drug

Pathophysiology (multifactorial):

• Drug effects on gingival fibroblasts → decreased collagenase activity (decreased degradation of connective tissue matrix) → accumulation of collagen
• Drug effects on keratinocyte growth factors
• Genetic predisposition
• PLAQUE and INFLAMMATION are MAJOR co-factors — excellent oral hygiene can prevent or minimize overgrowth, even in patients taking these drugs

Management of DIGO:

1. Periodontal therapy: Meticulous plaque control, scaling and root planing, professional maintenance
2. Improved oral hygiene: The most important non-pharmacologic intervention — patients with excellent hygiene develop less overgrowth
3. Drug substitution (in consultation with physician): Nifedipine → amlodipine or another CCB (amlodipine has less gingival effect); or switch to a non-CCB antihypertensive
4. Surgical excision (gingivectomy): For severe, persistent cases. Recurrence is common unless plaque control is maintained
5. Chlorhexidine oral rinse as adjunctive therapy

Anticoagulants and Antiplatelet Drugs

Warfarin (Coumadin)

Mechanism: Vitamin K antagonist → inhibits vitamin K-dependent synthesis of clotting factors II, VII, IX, X, and proteins C and S. Monitored by PT/INR.

Dental management:

• INR should be checked before surgical procedures (extractions, periodontal surgery, implant placement). An INR within the therapeutic range (usually 2.0-3.5 depending on the indication) is generally safe for dental procedures. Historically, an INR ≤3.5 was considered acceptable; current practice varies.
• Do NOT discontinue warfarin for routine dental procedures — the risk of thromboembolic events (stroke, embolism) from discontinuing anticoagulation far outweighs the risk of bleeding from dental procedures
• Local hemostatic measures are effective: pressure, sutures, oxidized cellulose (Surgicel), gelatin sponges (Gelfoam), tranexamic acid mouthwash
• Multiple extractions in a single appointment may require more extensive local hemostatic measures; consider staging procedures
• NSAIDs are relatively contraindicated (increased bleeding risk + GI toxicity with warfarin). Acetaminophen is the preferred analgesic
• Certain antibiotics (metronidazole, broad-spectrum antibiotics) can potentiate warfarin's effect → check INR

Direct Oral Anticoagulants (DOACs)

Examples: Apixaban (Eliquis) — Factor Xa inhibitor; Rivaroxaban (Xarelto) — Factor Xa inhibitor; Dabigatran (Pradaxa) — direct thrombin inhibitor; Edoxaban (Savaysa) — Factor Xa inhibitor.

Dental management:

• DOACs have shorter half-lives (8-17 hours) than warfarin
• For routine dental procedures (single extraction, non-surgical periodontal therapy), DOACs generally do NOT need to be discontinued
• For more extensive surgery, the decision to hold doses is made in consultation with the patient's physician; timing depends on the specific DOAC, renal function, and bleeding risk
• Local hemostatic measures as for warfarin
• No routine coagulation testing (DOACs do not require monitoring; standard PT/PTT does not reliably measure DOAC effect)
• NSAIDs relatively contraindicated

Antiplatelet Agents

Aspirin:

• Aspirin 81-325 mg daily for cardioprotection: DO NOT DISCONTINUE for dental procedures. The thrombotic risk from discontinuation exceeds the bleeding risk from the procedure.
• Local hemostatic measures effective
• Aspirin 325 mg or higher daily: same approach; continue, use local measures

Dual antiplatelet therapy (DAPT): Aspirin + P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel). Typically prescribed after coronary stent placement, acute coronary syndrome.

• Do NOT discontinue for routine dental procedures without consulting the patient's cardiologist. Premature discontinuation of DAPT after coronary stenting carries a HIGH risk of stent thrombosis (catastrophic — mortality up to 50%).
• Elective dental procedures should be DEFERRED if possible during the critical period post-stent (typically 3-6 months for drug-eluting stents, 1 month for bare-metal stents)
• If the procedure cannot be deferred, manage with local hemostatic measures

Other Cardiovascular Drugs: Oral Effects Summary

Clinical Application

Before treating a patient on cardiovascular medications, the dental hygienist should:

1. Review the medication list and identify the class of each cardiovascular drug
2. Assess for gingival overgrowth — particularly nifedipine, phenytoin, or cyclosporine
3. Check INR for warfarin patients before surgical procedures
4. Identify anticoagulant/antiplatelet use and plan hemostatic measures
5. Document oral findings (xerostomia, gingival overgrowth, lichenoid lesions, mucosal changes)
6. Communicate with the physician when drug substitution is considered (gingival overgrowth) or when the safety of continuing/perioperative management of anticoagulants is uncertain

Common Traps

• Thinking all CCBs cause gingival overgrowth equally — nifedipine is the most common culprit
• Discontinuing aspirin or warfarin for routine dental procedures — this is outdated and dangerous practice
• Confusing ACE inhibitor cough with xerostomia — it's a cough, not dry mouth (though concurrent xerostomia is possible)
• Forgetting that amlodipine is also a CCB but causes FAR less gingival overgrowth than nifedipine
• Thinking drug-induced gingival overgrowth is solely the drug's fault — plaque and inflammation are essential co-factors